Theralase Technologies Inc. V.TLT

RE:We fly if NML confirms they also added MonkeyPox to our list

[ScienceFirst]

Surprisingly, as per this new report below, there's no treatment for MonkeyPox. So the frenzy on certain stocks that could possibly have a treatment. 

So if NML confirms that our anti-viral platform also has the ability to destroy the MonkeyPox, then that could give our anti-viral platform additional valuation, with its versatility and efficiency to destroy lipid enveloped viruses like Zika, herpes, influenza, SARS-2-Cov and now MonkeyPox.  

BioNTech signed with Pfizer in 2018, for similar versatility.

Take a look at the type of contracts BioNtech then obtained from Pfizer:



2018 - BioNTech Signs a 425M$ Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza

August 16, 2018 – BioNTech AG, a rapidly growing biotechnology company focused on precise immunotherapies for the treatment of cancer and infectious disease, today announced that it has entered into a multi-year research and development (R&D) collaboration with Pfizer Inc. (NYSE: PFE) to develop mRNA-based vaccines for prevention of influenza (flu).

BioNTech will receive $120 million in upfront, equity and near-term research payments and up to an additional $305 million in potential development, regulatory and commercial milestone payments. In addition, BioNTech will receive up to double-digit tiered royalty payments associated with worldwide sales if the program reaches commercialization.


April 2020 - Pfizer and BioNTech Announce Further Details on a 748M$ Collaboration to Accelerate Global COVID-19 Vaccine Development | Pfizer

• BioNTech will receive an upfront payment of $185 million, including an equity investment of approximately $113 million, and be eligible to receive future milestone payments of up to $563 million for a potential total consideration of $748 million

Jan. 2022 - Pfizer and BioNTech Sign New 425M$ Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine | Pfizer

 

• BioNTech will receive $225 million upfront, including an upfront cash payment of $75 million and an equity investment of $150 million, and will be eligible to receive future approval and sales milestone payments totaling up to $200 million as well as a share of gross profits arising from future product sales
• Pfizer will receive an upfront payment of $25 million from BioNTech for its proprietary antigen sequences identified by Pfizer

Monkeypox Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027


New York, July 27, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Monkeypox Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027" - https://www.reportlinker.com/p06310354/?utm_source=GNW
The market growth can be attributed to the sudden outburst of the viral infection among the population across Europe and United States.

In the year 2003, monkeypox caused a commotion because it spread quickly, and the number of affected patients exceeded 40 in a matter of weeks.Although the disease spread was relatively well-controlled, the recent outbreak of infection and rapidly increasing cases pose a threat for another possible pandemic.

Hence, the demand for effective treatment, vaccination, and other rare disease therapeutics are expected to support the growth of the global monkeypox therapeutics market over the next five years.

There is currently no specific treatment or defined pharmaceutical for the disease, but symptomatic treatment is possible, and an increase in demand for pain and itch relief due to boils and rashes are positively influencing the growth of the global monkeypox therapeutics market.
Monkeypox is a viral infection that spreads like a highly communicable disease through mere touch and use of infected patient’s material. The virus is related to smallpox, and the vaccination and drugs used to control smallpox are also somewhat effective against monkeypox diseases.

Although no specific vaccine or treatment drug has yet been commercialised, research is still ongoing. Patients with compromised immunity, those suffering from chronic disease, certain skin conditions such as eczema, those recovering from a recent pandemic, and those suffering from other anti-viral infections are all at high risk of contracting the monkeypox.

Growing demand for timely vaccines and potential disease treatments may support the growth of the global monkeypox therapeutics market in the next five years.Governments are actively investing in the research and development of effective vaccines and drugs to control disease spread and treat affected patients.

In addition, the government is taking steps to promote drug development using genetic engineering tools in order to provide vaccination in the event that the virus evolves and affects a larger portion of the population.
Genomic sequencing for the virus would elucidate the specific infection-causing sequences, which could aid in the early diagnosis of the viral infection and the development of effective vaccines for the population at risk of infection in the coming years. Furthermore, rising healthcare expenditures by the population is fuelling growing investments for the developmen to new vaccines, which is likely to aid the global monkeypox therapeutics market in the next five years.
The global monkeypox therapeutics market segmentation is based on treatment, end user, regional distribution, and competitive landscape.Based on treatment, the market is divided into smallpox vaccine, antivirals, and vaccinia immune globulin (VIG).